Controlled degradation of stents

• US 7,794,495 B2
• Filed: 07/17/2006
• Issued: 09/14/2010
• Est. Priority Date: 07/17/2006
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Gale, David C., Huang, Bin, Hossainy, Syed Faiyaz Ahmed, Gueriguian, Vincent J.
• Primary Examiner(s): Eashoo; Mark
• Assistant Examiner(s): Heincer; Liam J
• Application Number:
  US11/488,928
• Publication Number:
  US 20080015686A1
• Time in Patent Office: 1,520 Days
• Field of Search: 623/1.15, 623/1, 623/11, 623/12, 623/1.49, 523/105, 523/113, 523/115, 523/128, 424/489, 424/501, 424/423, 528/354
• US Class Current: 623/1.49
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Stents fabricated from hydrolytically degradable polymers with accelerated degradation rates and methods of fabricating stents with accelerated degradation rates are disclosed.

Claims

1. A stent comprising a structural element, the structural element comprising a block polymer including:

a hydrolytically degradable polymer block; and

an acidic polymer block including a pendant acid group bonded to a protecting group, the acidic polymer block capable of cleaving from the polymer upon exposure to bodily fluids, wherein

the hydrolytically degradable polymer block comprises poly(L-lactide) and

the acidic polymer block is selected from the group consisting of polystyrene sulfonate and poly(2-acrylamido-2-methylpropanesulfonic acid).

2. The stent of claim 1, wherein the protecting group is a radiation sensitive protecting group.

3. The stent of claim 2, wherein the radiation sensitive protecting group is capable of being cleaved from the acid group upon exposure to radiation.

4. The stent of claim 3, wherein the radiation is selected from the group consisting of ultraviolet, x-ray, e-beam, laser, or gamma.

5. The stent of claim 1, wherein the acidic polymer block comprises polystyrene sulfonate.

6. The stent of claim 5, wherein the protecting group is N-BOC-4-amino-2,2′

-dimethylbutyl.

7. The stent of claim 1, wherein the acidic polymer block comprises poly(2-acroylamido-2-methylpropanesulfonic acid).

8. The stent of claim 7, wherein the protecting group is N-BOC-4-amino-2,2-dimethylbutyl.